**Trustee's report 31 December 2024** The Trustees present their report along with the accounts of the Friends of EORTC (the Charity) for the year ended 31 December 2024. The accounts have been prepared in accordance with the accounting policies set out on pages 16 to 18 and comply with the charity's trust deed, the Charities Act 2011 and ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102). ## **Structure, governance and management** The Charity was established under a Trust Deed in 1976 and is registered with the Charity Commission under charity number 272818. The Chairman, Comte Diego du Monceau de Bergendal, was appointed a trustee in 2015 on the retirement of the then Chairman, Sir Christopher Mallaby. His fellow trustee, Lady Solti was appointed a trustee in 1998, and Mr Edward Chandler was appointed on 7 October 2020, coinciding with the resignation of Mrs Victoria Agnew who had dedicated 22 years to her role with the organisation. Pr. Duncan Jodrell was appointed on 10 November 2021 to replace Lady Solti. Mrs Artis was appointed on 7 October 2022. Mr Edward Chandler resigned on March 1, 2023. There is no time limit on the tenure of the trustees. The trustees meet twice a year. The Board keeps the skill requirements for the Trustee Body under review and if a trustee permanently retires or additional trustees are required, the Board would put in place appropriate procedures to recruit the new trustee(s). The Board would also ensure that appropriate induction and training is provided to all new trustees. ## **Statement of trustees' responsibilities** The trustees are responsible for preparing the trustees' report and accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales requires the trustees to prepare accounts for each fiscal year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these accounts, the trustees are required to: - select suitable accounting policies and then apply them consistently; - observe the methods and principles in the Charities SORP; - make judgements and estimates that are reasonable and prudent; - state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the accounts; and - prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation. The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. ## **Risk management** The Charity does not have any employees, significant contracts or material investments nor is the Charity dependent on grant funding from external sources to maintain its charitable activities. As a result of these limited activities, the Charity is exposed to few significant risks. The principal risk faced by the Charity would be the failure to generate sufficient donations to cover the costs of organising a fundraising event. This is mitigated by the Charity, wherever possible, by raising funds in advance of costs being incurred; carefully planning its fundraising events; targeting known supporters of the Charity and closely monitoring fundraising costs and donations. ## **Objectives and Activities** EORTC was set up in 1962 by leading cancer specialists in the EU and Switzerland in order that research on treatment of cancer could be co-ordinated and carried out on a European scale, thereby avoiding duplication and achieving economies of time and money. The primary object of the Charity, as stated in its governing document, is to support the charitable objects and purposes of EORTC Cancer Research Fund AISBL (ECRF), a charity registered in Belgium. The ECRF was established in 1976, as The EORTC Foundation. This charitable trust was established to support the activities of the EORTC. The ECRF supports the activities of the EORTC through annual grant payments to the EORTC which are used by the EORTC to fund research into cancer treatments. The Friends of EORTC supports the ECRF by organising fundraising events in the UK and by a major fundraising initiative. The funds raised by the Friends of EORTC are then used to support the activities of the ECRF. The Friends of EORTC makes donations to EORTC on an ad- hoc basis, as determined by the Trustees. ## **Achievements and Performance** ## **Financial review** The income of the charity declined over that of the previous year, however the major fundraising initiative continued, and national and private donations were received in 2024. The charity received donations from its supporters amounting to £40,857 (2023 - £77,102). Total expenditure: £ 40,857 (2023 - £ 77,102). The charity remains financially stable with a small loss. ## **Interest and foreign exchange** The Charity earned £557 in interest in 2024 (2023 – £1,199) and booked no foreign exchange gains (2023 – none). ## **Walgreen’s Boots Alliance** EORTC Cancer Research Fund (formerly the EORTC Charitable Trust) has been in partnership with Walgreens Alliance Boots (WBA, then Alliance Boots) since late 2011. The partnership focused on creating the first panEuropean biobank in advanced colorectal cancer, now fully operational in Dresden. WBA committed to raising €5 million over five years to support this key research infrastructure. Scientific planning for the project, named SPECTAcolor, began in 2012 with the development of biobanking facilities and identification of participating hospitals. The success of SPECTAcolor led EORTC to expand to other cancer types, culminating in 2018 with the launch of SPECTA, a unified platform for all cancers, including rare ones, with a central biobank in Luxembourg. That same year, WBA renewed its support through a new €5 million, five-year agreement, reaffirming SPECTA’s position as a leading translational research infrastructure In October 2022, WBA and EORTC launched a new three-year fundraising effort to raise €1.8 million for the OligoRARE study and the E²-RADIatE platform, which aims to define optimal radiation therapy practices for future clinical standards. E²-RADIatE is the only pan-European platform dedicated to radiation oncology research, integrating clinical data with diagnostic imaging, treatment data, economic outcomes, and patient-reported experiences to enhance patient-centred care. The platform includes several observational cohort studies and clinical trials: - **OligoCare** (EORTC 1822-RP): the first activated cohort, focuses on patients with oligometastatic disease (cancer spread to a limited number of organs), aiming to identify factors influencing survival after radical radiotherapy. Cancer types studied include breast, lung, prostate, and colorectal. - **ReCare** (EORTC 2011-RP): collects real-world data on high-dose re-irradiation in cases of recurrence or secondary cancers. It aims to provide evidence on efficacy and safety of re-treatment in the modern radiotherapy era. - **OligoRARE** (EORTC 1945): a randomized clinical trial evaluating whether SABR (Stereotactic Ablative Body Radiotherapy) improves survival compared to standard care in patients with oligometastatic rare cancers. - **SPRINT** (EORTC 2387): is the first pan-European Trial within Cohorts (TwiCs), leveraging real-world data from the OligoCare cohort to evaluate treatment strategies for patients with oligometastatic breast, prostate, lung, and colorectal cancers. The study aims to determine whether a single fraction of stereotactic body radiotherapy (SBRT) can be as effective as multi-fraction SBRT, potentially reducing treatment burden while improving patient experience and quality of life. E²-RADIatE supports radiotherapy’s role as a cornerstone of cancer care, used by half of all patients during treatment. By leveraging advanced technology and structured data collection, the platform contributes to reducing inequities in care and improving outcomes across Europe. ## **Alliance Healthcare (to be renamed Cencora)** In June 2021, Walgreens Boots Alliance sold its Alliance Healthcare businesses to AmerisourceBergen, now renamed Cencora. Alliance Healthcare, now a wholly owned subsidiary of Cencora, supported the SPECTA platform under its new ownership with half of the initial pledge be raised by the end of the agreement in 2023. In 2024, Cencora contributed an additional $100K towards the platform. The funds raised through the partnership are estimated to cover the current activities of the platform until 2027. ## **Alliance Healthcare (soon to be renamed Cencora) contributions** From June 1st, 2021, to December 2024, 2023, Alliance Healthcare has raised a total of €2,192,401.24. ## **AMRC - Association of Medical Research Charities** Since October 2014, the Friends of EORTC has been a member of AMRC. This membership provides clear benefits for EORTC and for the costs related to its international clinical studies being opened or adopted in the UK. Membership of AMRC helps the EORTC to qualify as eligible under the UK NHS AcoRD Programme under which certain clinical research costs are met by the National Health Service. Under AcoRD, AMRC charities that fund in open competition do not have to pay these costs. The work will be done by the NIHR Clinical Research Networks or will be covered by the infrastructure support funding going to NHS trusts and universities. EORTC, through the Friends of EORTC, is in good standing for support from the NIHR and NHS for other study related costs as described above. ## **UK Liaison Office** A Liaison Office has been established in the UK between the National Cancer Research Institute (NCRI), EORTC and CR-UK to promote better communications between these three organisations and to facilitate the adoption of EORTC's international studies in the UK and the extension of UK studies into Europe. The Friends of EORTC supports this initiative by currently contributing one third of the costs of the salary of the Liaison Officer, based at the University of Leeds. Since 2017, the costs of the Liaison Office in Leeds have been shared between EORTC and CR-UK. ## **Investment powers, policy, and performance** The Charity does not hold investments other than cash held on an interest bearing deposit on a short-term basis. These funds are held in the Charity's bank account, held by Coutts. ## **Grant making policy** The Charity makes grants to the EORTC and to the EORTC Cancer Research Fund and for fellowships, as direct grants or on an ad-hoc basis. ## **Reserves** The Charity makes grants to the EORTC as cash becomes available, retaining sufficient funds to cover the potential outgoings associated with future fundraising events. The Charity does not enter on-going commitments and therefore does not need to ensure a steady flow of income. For this reason, the trustees do not consider it appropriate to maintain a target level of reserves. The funds raised by the Charity are held as deposits on call accounts until such time that the Trustees wish to make grants or donations directly to the EORTC to support their ongoing activities. ## **Going concern** The Trustees of the charity have determined that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion, based on available information at the date of approval of the financial statements, that the charity will have sufficient resources to meet its liabilities as they fall due. They do not believe that there are concerns regarding the charity's ability to continue as a going concern. |**EXPENSES**
**Act 2018**
**Act 2019**
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**
**Jan-24**
**Feb-24**
**Mar-24**
**Apr-24**
**May-24**
**ACT 2024**
**LO**
Liaison Ofce Leeds
34,798
39,442
34,456
42,674
41,700
42,273
11,708.33
-11,708.33
32,899.26
Liaison Ofce Leeds VAT (non ded 20%)
6,579.85
Liaison Ofce Leeds corr
-8,521
-6,574
0
-7,112
-8,340
0.00
**TOTAL**
**34,798**
**30,921**
**27,882**
**42,674**
**34,587**
**33,933**
**0**
**0**
**11,708**
**-11,708**
**0**
**39,479.11**
**ADMIN**
Accountng
Audit (#613110)
3,060
3,150
3,330
3,480
3,960
4,200
1,102.50
-1,102.50
0.00
Audit (regul. Y-1)
210
0
120
-12
0
0.00
Chartered accountant
1,200.00
Consultancy
0
0
0
0
0
0
0.00
Subscriptons (AMRC)
446.90
548
552
803
1,126
665
52.08
52.08
52.12
41.67
41.67
531.31
Monthly fee (just-giving)
216.00
216
216
216
162
216
18.00
18.00
18.00
18.00
18.00
216.00
Insurances
0.00
0
0
0
0
0
0.00
**TOTAL**
**3,723**
**4,124**
**4,098**
**4,619**
**5,236**
**5,081**
**70**
**70**
**1,173**
**-1,043**
**60**
**1,947.31**
Expenditure EORTC CRF
0
0
0
0
0
0
0.00
Gif Aid cancellaton
0
0
0
0
0
3,700
0.00
Expenditure EORTC HQ Core Grant
0
0
0
0
0
0
0.00
Transfer EORTC (WBA): SPECTA
0
1,158,496
129,538
161,837
0
0
0.00
Transfer EORTC (AmerisourceBergen): SPECTA
46,070
154,949
1
36.25
Transfer EORTC (WBA): E2-RADiate
0
33,821
33,821
0.00
Transfer China Challenge
3,713
7,842
0
0.00
Transfer EORTC (ECRF 40th anniv.)
218,496
0
0
0
0
0.00
Transfer EORTC (EORTC 60th anniv.)
1,500
0
0.00
Transfer Strass II
25,000
0
0.00
Grant Snowman
0
0
0
0
33,872
0
0.00
Grant Grierson
0
0
0
0
27,739
0
0.00
Bank charges
789
744
470
756
642
559
121.75
70.00
590.60
Currency exchange
94
0
0
18
8
0
0.00
Other fnancial charges (Justgiving)
15
462
65
90
9
7
0.36
4.02
Other fnancial charges (Ammado/Stripe)
0
0
0
0
8
0
0.00
**TOTAL COSTS**
**39,419**
**1,413,243**
**162,052**
**259,776**
**291,392**
**77,103**
**70**
**70**
**13,003**
**-12,751**
**33,951**
**42,057.29**|**EXPENSES**
**Act 2018**
**Act 2019**
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**
**Jan-24**
**Feb-24**
**Mar-24**
**Apr-24**
**May-24**
**ACT 2024**
**LO**
Liaison Ofce Leeds
34,798
39,442
34,456
42,674
41,700
42,273
11,708.33
-11,708.33
32,899.26
Liaison Ofce Leeds VAT (non ded 20%)
6,579.85
Liaison Ofce Leeds corr
-8,521
-6,574
0
-7,112
-8,340
0.00
**TOTAL**
**34,798**
**30,921**
**27,882**
**42,674**
**34,587**
**33,933**
**0**
**0**
**11,708**
**-11,708**
**0**
**39,479.11**
**ADMIN**
Accountng
Audit (#613110)
3,060
3,150
3,330
3,480
3,960
4,200
1,102.50
-1,102.50
0.00
Audit (regul. Y-1)
210
0
120
-12
0
0.00
Chartered accountant
1,200.00
Consultancy
0
0
0
0
0
0
0.00
Subscriptons (AMRC)
446.90
548
552
803
1,126
665
52.08
52.08
52.12
41.67
41.67
531.31
Monthly fee (just-giving)
216.00
216
216
216
162
216
18.00
18.00
18.00
18.00
18.00
216.00
Insurances
0.00
0
0
0
0
0
0.00
**TOTAL**
**3,723**
**4,124**
**4,098**
**4,619**
**5,236**
**5,081**
**70**
**70**
**1,173**
**-1,043**
**60**
**1,947.31**
Expenditure EORTC CRF
0
0
0
0
0
0
0.00
Gif Aid cancellaton
0
0
0
0
0
3,700
0.00
Expenditure EORTC HQ Core Grant
0
0
0
0
0
0
0.00
Transfer EORTC (WBA): SPECTA
0
1,158,496
129,538
161,837
0
0
0.00
Transfer EORTC (AmerisourceBergen): SPECTA
46,070
154,949
1
36.25
Transfer EORTC (WBA): E2-RADiate
0
33,821
33,821
0.00
Transfer China Challenge
3,713
7,842
0
0.00
Transfer EORTC (ECRF 40th anniv.)
218,496
0
0
0
0
0.00
Transfer EORTC (EORTC 60th anniv.)
1,500
0
0.00
Transfer Strass II
25,000
0
0.00
Grant Snowman
0
0
0
0
33,872
0
0.00
Grant Grierson
0
0
0
0
27,739
0
0.00
Bank charges
789
744
470
756
642
559
121.75
70.00
590.60
Currency exchange
94
0
0
18
8
0
0.00
Other fnancial charges (Justgiving)
15
462
65
90
9
7
0.36
4.02
Other fnancial charges (Ammado/Stripe)
0
0
0
0
8
0
0.00
**TOTAL COSTS**
**39,419**
**1,413,243**
**162,052**
**259,776**
**291,392**
**77,103**
**70**
**70**
**13,003**
**-12,751**
**33,951**
**42,057.29**|**EXPENSES**
**Act 2018**
**Act 2019**
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**
**Jan-24**
**Feb-24**
**Mar-24**
**Apr-24**
**May-24**
**ACT 2024**
**LO**
Liaison Ofce Leeds
34,798
39,442
34,456
42,674
41,700
42,273
11,708.33
-11,708.33
32,899.26
Liaison Ofce Leeds VAT (non ded 20%)
6,579.85
Liaison Ofce Leeds corr
-8,521
-6,574
0
-7,112
-8,340
0.00
**TOTAL**
**34,798**
**30,921**
**27,882**
**42,674**
**34,587**
**33,933**
**0**
**0**
**11,708**
**-11,708**
**0**
**39,479.11**
**ADMIN**
Accountng
Audit (#613110)
3,060
3,150
3,330
3,480
3,960
4,200
1,102.50
-1,102.50
0.00
Audit (regul. Y-1)
210
0
120
-12
0
0.00
Chartered accountant
1,200.00
Consultancy
0
0
0
0
0
0
0.00
Subscriptons (AMRC)
446.90
548
552
803
1,126
665
52.08
52.08
52.12
41.67
41.67
531.31
Monthly fee (just-giving)
216.00
216
216
216
162
216
18.00
18.00
18.00
18.00
18.00
216.00
Insurances
0.00
0
0
0
0
0
0.00
**TOTAL**
**3,723**
**4,124**
**4,098**
**4,619**
**5,236**
**5,081**
**70**
**70**
**1,173**
**-1,043**
**60**
**1,947.31**
Expenditure EORTC CRF
0
0
0
0
0
0
0.00
Gif Aid cancellaton
0
0
0
0
0
3,700
0.00
Expenditure EORTC HQ Core Grant
0
0
0
0
0
0
0.00
Transfer EORTC (WBA): SPECTA
0
1,158,496
129,538
161,837
0
0
0.00
Transfer EORTC (AmerisourceBergen): SPECTA
46,070
154,949
1
36.25
Transfer EORTC (WBA): E2-RADiate
0
33,821
33,821
0.00
Transfer China Challenge
3,713
7,842
0
0.00
Transfer EORTC (ECRF 40th anniv.)
218,496
0
0
0
0
0.00
Transfer EORTC (EORTC 60th anniv.)
1,500
0
0.00
Transfer Strass II
25,000
0
0.00
Grant Snowman
0
0
0
0
33,872
0
0.00
Grant Grierson
0
0
0
0
27,739
0
0.00
Bank charges
789
744
470
756
642
559
121.75
70.00
590.60
Currency exchange
94
0
0
18
8
0
0.00
Other fnancial charges (Justgiving)
15
462
65
90
9
7
0.36
4.02
Other fnancial charges (Ammado/Stripe)
0
0
0
0
8
0
0.00
**TOTAL COSTS**
**39,419**
**1,413,243**
**162,052**
**259,776**
**291,392**
**77,103**
**70**
**70**
**13,003**
**-12,751**
**33,951**
**42,057.29**| |---|---|---| ||**39,419**
**1,413,243**
**162,052**
**259,776**
**291,392**
**77,103**
**70**
**70**
**13,003**
**-12,751**
**33,951**|**42,057.29**| |**INCOME**
**Act 2018**
**Liaison Ofce**
EORTC HQ
34,797.60
Corr
**Unrestricted Donatons**
Ammado/Stripe
0.00
Justgiving
10.00
ECRF 40th anniversary
0.00
EORTC 60th anniversary
China Challenge
Others
0.00
**10.00**
**WBA**
CSR Program 1 & 2/1
104,183.51
Monaco Gala
**104,183.51**
**WBA**
E2-RADiate
**AmerisourceBergen**
CSR Program 2/5
**CAC**
Strass II (1809)
**Natonal donatons**
Hong-Kong (through EORTC)
UK (CRUK stopped)
**0.00**
**Financial interests**
Bank interests
377.41
Currency diferences
79.46
Other fnancial income
0.00
**456.87**
**TOTAL REVENUE**
**139,447.98**
0.00|**Act 2019**
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**
**ACT 2024**
39,442.20
34,455.50
42,674.10
41,699.76
42,272.93
39,479.11
-8,521.34
-6,573.71
0.00
-7,112.35
-8,339.95
0.00
0.00
0
286.44
477.68
0.00
50.00
50.00
0
40.00
20.00
0.00
0.00
0.00
0
0
0
0
0.00
1,500
0
0.00
5,037.29
19,339
5,184.38
0.00
0.00
0.00
160.00
156
0
0
20
0.00
**5,247.29**
**19,494.57**
**5,510.82**
**1,997.68**
**20.00**
**50.00**
284,938.18
129,599
161,883.57|**Act 2019**
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**
**ACT 2024**
39,442.20
34,455.50
42,674.10
41,699.76
42,272.93
39,479.11
-8,521.34
-6,573.71
0.00
-7,112.35
-8,339.95
0.00
0.00
0
286.44
477.68
0.00
50.00
50.00
0
40.00
20.00
0.00
0.00
0.00
0
0
0
0
0.00
1,500
0
0.00
5,037.29
19,339
5,184.38
0.00
0.00
0.00
160.00
156
0
0
20
0.00
**5,247.29**
**19,494.57**
**5,510.82**
**1,997.68**
**20.00**
**50.00**
284,938.18
129,599
161,883.57| |---|---|---| |||| ||632,168.41|| ||**917,106.59**
**129,599.30**
**161,884**
**0**
**0**
**0**
33,543.65
0.00
46,111.54
154,957.50
284.03
36.25
25,000.00|| |||| ||**0.00**
**0.00**
**0.00**
**0.00**
**0.00**
**0.00**
681.30
125
25.80
202.83
1,199.17
557.25
0.00
0.00
0.00
0.00
0.00
0.00
3.00
0.00
0.00
0.00
0.00
0.00
**684.30**
**125.33**
**25.80**
**202.83**
**1,199.17**
**557.25**
**953,959.04**
**177,100.99**
**256,205.83**
**216,745.42**
**68,979.83**
**40,122.61**
0.00
0.00
0.00
0.00
0.00
0.00|| ## **FRIENDS OF EORTC** **Income statement (GBP)** - December 30, 2024 |**INCOME**|**Act 2020**|**Act 2021**|**Act 2022**|**Act 2023**|**Act 2024**|**EXPENSES**|**Act 2020**|**Act 2021**|**Act 2022**|**Act 2023**|**Act 2024**| |---|---|---|---|---|---|---|---|---|---|---|---| |**Liaison Ofce Leeds (EORTC)**|27,882|42,674|34,587|33,933|39,479|**Liaison Ofce Leeds**|27,882|42,674|34,587|33,933|39,479| ||||||||||||| |**Unrestricted donatons**
Others (Stripe, Justgiving,…)|156|326|498|20|50|**Administraton**|4,098|4,619|5,236|5,081|1,947| |ECRF 40th anniversary||||||Gif Aid||||3,700|| |EORTC 60th anniversary|||1,500|0|0|**Transfer EORTC**||3,713|1,500||0| ||||||||||||| |**Restricted donatons**
Grierson
Snowman|||||0
0|**Grierson**
**Snowman**|||33,872
27,739||0
0| |**Mc Millan**
GWOC China Challenge|19,339|5,184||||**GWOC China Challenge**|||7,842||0| |**WBA**
CSR Programs 1& 2/1|129,599|161,884||||**SPECTA**(WBA)|129,538|161,837|||0| |CSR Program 2/2
**Cencora**(AmerisourceBergen)||46,112|154,958|284|36|**SPECTA**(Cencora)||46,070|154,949|1|36| |**WBA**
E2-Radiate||||33,544|0|**E2-RADiate**(WBA)||||33,821|0| |**Climbers Against Cancer**
Strass II (1809)|||25,000||0|**Strass II**(CAC)|||25,000||0| ||||||||||||| |**Financials income**|125|26|203|1,199|557|**Financial costs**|534|864|668|566|595| ||||||||||||| |**TOTAL REVENUE**|**177,101**|**256,206**|**216,745**|**68,980**|**40,123**|**TOTAL COSTS**|**162,052**|**259,776**|**291,392**|**77,103**|**42,057**| ||0.00
0.00
0.00
0.00||||0.00||0.00
0.00
0.00
0.00||||0.00| |**Surplus of theyear(+) / (-)**|15,049|-3,570|-74,647|-8,123|-1,935||||||| |**FRIENDS OF EORTC**|Income Statement
December 31, 2024
in GBP
**Act 2020**
**Act 2021**
**Act 2022**
**Act 2023**| |---|---| |**I.**
**Operatng Income**(A+B+C)|**176,976**
**256,180**
**216,543**
**64,081**| |**A. Turnover**|**176,976**
**256,180**
**216,543**
**64,081**| |A1. Unrestricted contributons
Natonal cancer leagues|| |A2. Unrestricted donatons
A3. Restricted donatons
**B. Other operatng income**|156
326
1,998
-3,680
176,820
255,854
214,545
67,761
**0**
**0**
**0**
**0**| |**II.**
**Operatng Charges**(A+B+C+D)|**-161,518**
**-258,912**
**-290,725**
**-72,837**| |**A. Services and other goods**|**-31,980**
**-47,293**
**-39,823**
**-39,014**| |Ofces|| |Administraton
Liaison Ofce Leeds (EORTC)
**D. Other operatng charges**
Transfert to EORTC|-4,098
-4,619
-5,236
-5,081
-27,882
-42,674
-34,587
-33,933
**-129,538**
**-211,619**
**-250,902**
**-33,823**| |**III.**
**Operatng result**(I - II)|**15,458**
**-2,732**
**-74,182**
**-8,756**| |**IV. Financial result**|-409
-838
-465
633| |**VI.**
**Proft for the period** (III - IV - V)|**15,049**
**-3,570**
**-74,647**
**-8,123**| ## Friends of EORTC - Income statement December 31, 2024 in GBP |||**2021**|**2022**|**2023**| |---|---|---|---|---| |**I**|**OPERATING INCOME**|**256,180**|**216,543**|**64,081**| ||Unrestricted donatons|326|1,998|-3,680| ||Restricted donatons|213,179|179,958|33,828| ||Liaison Ofce Leeds (EORTC)|42,674|34,587|33,933| |**II**|**OPERATING CHARGES**|**-258,912**|**-290,725**|**-72,837**| ||Ofces|||| ||Administraton|-4,619|-5,236|-5,081| ||Travel|||| ||Liaison Ofce Leeds (EORTC)|-42,674|-34,587|-33,933| ||Transfert to EORTC|-211,619|-250,902|-33,823| |**III**|**OPERATING PROFIT (I + II)**|**-2,732**|**-74,182**|**-8,756**| |**IV-V**|**Financial result**|-838|-465|633| |**VI**|**Surplus/Loss for the period**(before taxes)|**-3,570**|**-74,647**|**-8,123**| |**VII**|**Surplus/Loss for the period**(afer taxes)|**-3,570**|**-74,647**|**-8,123**| **2024** **39,565** 50 36 39,479 **-41,463** -1,947 -39,479 -36 **-1,897** -37 **-1,935** **-1,935** Balance Sheet Statement December 31, 2024 in GBP ## **FRIENDS OF EORTC** **Act 2018 Act 2019 Act 2020 Act 2021 Act 2022** ||**ASSETS**|||||| |---|---|---|---|---|---|---| ||**FIXED ASSETS**|**0**|**0**|**0**|**0**|**0**| |**II.**|Intangible assets|||||| |**III.**|Tangible assets|||||| |**IV.**|Financial assets (Rent deposit)|||||| ||**CURRENT ASSETS**|**591,241**|**134,209**|**277,661**|**356,884**|**238,349**| |**VII.**|Amounts receivable < 1 year|||||| |**VIII.**Investments - savings||||||| |**IX.**|Cash at bank and in hand|**552,682**|**90,970**|**239,414**|**310,367**|**184,413**| ||Couts (GBP) - current account|750|750|750|750|750| ||Couts (GBP) - business account|551,932|90,220|238,664|309,617|183,663| |**X.**|Deferred charges and accrued income|38,559|43,239|38,247|46,516|53,936| ||**TOTAL**|**591,241**|**134,209**|**277,661**|**356,884**|**238,349**| ||**LIABILITIES**|||||| ||**EQUITY**|**550,352**|**91,069**|**106,117**|**102,547**|**27,900**| |**I.**|Associaton funds|||||| |**IV.**|Restricted funds - WBA|241,851||||| |**IV.**|Restricted funds - Snowman (Fellowship)|33,872|33,872|33,872|33,872|| |**IV.**|Restricted funds - Grierson (Fellowship)|27,739|27,739|27,739|27,739|| |**IV.**|Restricted funds - ECRF 40th anniversary|218,496||||| |**V.**|Surplus (loss) carried forward|28,395|29,458|44,506|40,936|27,900| ||Surplus (loss) of the period|||||| ||**CREDITORS**|**40,889**|**43,140**|**171,544**|**254,337**|**210,449**| |**IX.**|Amounts payable < 1 year|26,276|0|3,804|234|0| ||A. Financial debts|||||| ||B. Trade debts|26,276|0|3,804|234|0| ||C. Advances received on contracts in progress|||||| ||D. Taxes, remuneraton and social security|||||| ||E. Other amounts payable|||||| |**X.**|Accrued charges and deferred income|14,612|43,140|167,740|254,103|210,449| ||**TOTAL**|**591,241**|**134,209**|**277,661**|**356,884**|**238,349**| ## FRIENDS OF EORTC- Balance sheet statement December 31, 2024 in GBP |**II.**
**III.**
**IV.**
**VII.**
**VIII.**|**ASSETS**
**2023**
**2024**
**FIXED ASSETS**
**0**
**0**
**0**
Intangible assets
0
0
0
Tangible assets
0
0
0
A. Plant, machinery and equipment
0
0
0
B. Furniture
0
0
0
C. Assets under constructons and advance
0
0
0
Financial assets (Rent deposit)
0
0
0
**CURRENT ASSETS**
**100,913**
**49,797**
**-51,116**
Amounts receivable < 1 year
0
0
E. Trade debtors
0
0
F. Other amounts receivable
0
0
Investments
0
0|**ASSETS**
**2023**
**2024**
**FIXED ASSETS**
**0**
**0**
**0**
Intangible assets
0
0
0
Tangible assets
0
0
0
A. Plant, machinery and equipment
0
0
0
B. Furniture
0
0
0
C. Assets under constructons and advance
0
0
0
Financial assets (Rent deposit)
0
0
0
**CURRENT ASSETS**
**100,913**
**49,797**
**-51,116**
Amounts receivable < 1 year
0
0
E. Trade debtors
0
0
F. Other amounts receivable
0
0
Investments
0
0|**I.**
**IV.**
**IV.**
**IV.**
**IV.**
**V.**
**V.**
**IX.**| |---|---|---|---| |**IX.**
**X.**|Cash at bank and in hand
58,483
18,955
-39,528
Deferred charges and accrued income
42,429
30,842
-11,587||**X.**| ||||| ||**TOTAL ASSETS**
**100,913**
**49,797**||| Var. (Y/Y-1) 0.82886 |**LIABILITIES**
**2023**
**2024**
**EQUITY**
**19,777**
**17,842**
**-1,935**|**LIABILITIES**
**2023**
**2024**
**EQUITY**
**19,777**
**17,842**
**-1,935**|**LIABILITIES**
**2023**
**2024**
**EQUITY**
**19,777**
**17,842**
**-1,935**| |---|---|---| |Associaton funds
Restricted funds - WBA
Restricted funds - Gillings Foundaton
Restricted funds - Snowman (Fellowship)
Restricted funds - Grierson (Fellowship)|0
0
0
0
0|| |Surplus (loss) carried forward
19,777
19,777
1935||| |Surplus (loss) of the period|-,
-1,935|| |**CREDITORS**
**81,135**
**31,955**
**-49,181**
Amounts payable < 1 year
47,313
30,717
-16,596||| |A. Financial debts|0|| |B. Trade debts
47,313
30,717
-16,596||| |C. Advance payments on contracts in progress
D. Taxes, remuneraton and social security|0
0|| |E. Other amounts payable
0
0
0||| |Accruals and deferred income
33,823
1,238
-32,585||| |||| |**TOTAL LIABILITIES**
**100,913**
**49,797**||| |||| ||**2016**|**2017**|**2018**|**2019**|**2020**|**2021**|**2022**|**2023**|**2024**| |---|---|---|---|---|---|---|---|---|---| |Fee|2,550.00|2,550.00|2,625.00|2,700.00|2,800.00|2,890.00|3,300.00|3,500.00|| |VAT|510.00|510.00|525.00|540.00|560.00|578.00|660.00|700.00|| ||3,060.00|3,060.00|3,150.00|3,240.00|3,360.00|3,468.00|3,960.00|4,200.00|0.00| |||0.0%|2.9%|2.9%|3.7%|3.2%|14.2%|6.1%|-100.0%| ||**A6**||**A7**|**A7**|| |---|---|---|---|---|---| |From|4/1/2023|From|4/1/2024|4/1/2025|| |To|3/31/2024|To|3/31/2025|3/31/2026|| |Gross salary 1.5 FTE|47,340|Gross salary|45,148|46,503|**91,651**| |||||3.0%|| |Overheads and Non Pay|17,406|Overheads and Non Pay|13,287|13,626|**26,913**| ||36.8%||29.4%|29.3%|29.4%| |Pension/NI contributon|14,283|Pension/NI contributon|11,747|12,138|**23,885**| ||30.2%||26.0%|26.1%|26.1%| |TOTAL|**79,029**|TOTAL|**70,182**|**72,267**|**142,449**| |Contributons||Contributons|||| |Leeds|47,417|Leeds 40%|28,073|28,907|**56,980**| ||60.0%|EORTC 60%|42,109|43,360|**85,469**| |EORTC|31,612||**70,182**|**72,267**|**142,449**| ||40.0%||||| |2024|7,903.00|2024|31,581.90||| |Invoiced|7,301.81|Invoiced|25,597.47||| 'ei'heads aiid noii-pay costs iiieiilioiied lli Ihe lable aboi.'e shoiild i11cli￿¢,¢0L.ei. all extra costs associated perfoiiiliii? EORTC Liaisoii Office acli14ries %iicli as local office ii)fi'a%ttiicliwe (iJ)cl. office li￿tella]S & eqiiipiiielll. ￿ siippoi'i) alldiiieelillÈS tsai'els costs i'elaled lo pei'foiii)iiig of boili LOS fillictloll (i.e.. EGAM atteiidaJ)ce. alleiidaiice lo C.RUK-NCRI-EORTC bla1￿1￿1 llieeillig). Subscripti Expenditures |Act|2018|446.90|38,520.50|1.16%| |---|---|---|---|---| |Act|2019|548.01|35,044.87|1.56%| |Act|2020|551.81|31,979.60|1.73%| |Act|2021|802.94|47,293.04|1.70%| |Act|2022|1,125.65|39,823.06|2.83%| |Act|2023|665.42|39,014.40|1.71%| |Act|2024|665.42|40,226.42|1.65%| Please note that although fees are not being raised this year rf your SFend on research year has taken you into a b￿ner or lower bracKet you won't ￿ charged the same amoL year. To help you wrth YOUT budgeting I have included the bandings here- Ihese figure% memter beneffts including events. Band UK research exp•nditure >£40,000.000 £25,000.000 - £39,999,999 £12,500,00- £24.999.999 £7.500,000- £12.499.999 £5.000,000- £7.499.999 £3,750,000- £4.999.999 £2,500,000- £3,749.999 £1,500,000- £2,499.999 £850.000- £1,499,999 £650.000- £849,999 £450.000- £649,999 £350.000- £449,999 £250,000 - £349,999 £0- £249,999 2024-5 subscn"pts"on fèe Capped Capped £33,645 £18 325 £11745 £8,435 £6,160 £4,305 £2,660 £1,T15 £1,215 £850 £625 £51)0 10 12 13 14 If you have any questions, please do not hesitate to get in louch. in the last Inl as last > cover all Independent examlner's report to the trustees of the Frlends of EORTC I report to the trustees on my examination of the accounts of the Friends of EORTC for the yearended 31 December2024. Responslblutles and ba818 of report As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the AcV}. I report in respect of my examination of the Trust's accounts carried out under section 145 ofthe 2011 Act and in carryingout myexamination I havefollowed aiithe applicable Directions given bythe Charity Commission under section 145(5}{bl of the Act. Independent examlner's statement. I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giifjng me cause to believe that in any material respect: 1. accounting records were not kept in respect of the Trust as required by section 130 of the Act: or 2. the accounts do not accord with those records: or 3. the accounts do not comply with the applicable requirements conceming the form and content of accounts set out in the Charities !AccountS and Reports) Regulations 2008 otherthan any requirementthatthe ecccjuntsgtve a'true and fairviewwhich is not a matterconsidered as part of an indeperidpny examination. I have no concerns and have come across rio <)tber matters in connection with the examination to which attention should be drawn in this report in orderto enable a properunderstandingof the accounts to be reached. Signed: Name: Melissa Foux Relevant professionalqualification or membership of professional bodies lif any): Chartered Accountant ICAEW Membership number8313878 Address: 56 FLanders Road London W4 1NG Date: 1111012025